Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May 1;156(9):1783-1790.
doi: 10.1002/ijc.35294. Epub 2024 Dec 19.

Interval cancer risk after the upper age limit of screening has been reached: Informing risk stratification in FIT-based colorectal cancer screening

Affiliations

Interval cancer risk after the upper age limit of screening has been reached: Informing risk stratification in FIT-based colorectal cancer screening

Brenda J van Stigt et al. Int J Cancer. .

Abstract

Upper age limits are currently fixed for all fecal immunochemical test (FIT)-based colorectal cancer (CRC) screening programs. A risk-stratified upper age limit may be beneficial. Therefore, we assessed differences in interval CRC risk among individuals who had reached the upper age limit of screening (75 years). Individuals with a negative FIT (<47 μg Hb/g feces) in the final round of the Dutch CRC screening program were selected from the national screening database and linked to the national cancer registry to identify CRCs diagnosed within 24 months (interval CRCs). Survival analyses assessed whether sex and last fecal hemoglobin (f-Hb) concentration were associated with interval CRC risk. A multivariable logistic regression assessed whether sex, last f-Hb concentration and screening round were associated with stage distribution (early vs. late). Last f-Hb concentrations were considered detectable when they were >0 μg Hb/g feces. Among 305,761 individuals with a complete follow-up (24 months), 661 were diagnosed with interval CRC (21.6 per 10,000 negative FITs). Individuals with detectable f-Hb (15%) were 5 times more likely to be diagnosed with interval CRC than those without (HR 4.87, 95%CI: 4.19-5.65). Moreover, their cancers were more often detected at a late stage compared to individuals without detectable f-Hb (OR 1.45, 95%CI: 1.06-2.01). Our results show that interval CRC risk among individuals aged ≥75 differs substantially by last f-Hb concentration, indicating a uniform age to stop screening is suboptimal. Future research, taking into account multiple screening rounds and FIT results, should determine the optimal risk-stratified screening strategy.

Keywords: fecal immunochemical test; hemoglobin concentration; personalized screening; screening colorectal cancer.

PubMed Disclaimer

Conflict of interest statement

MS: Received research support from Sentinel, Sysmex, Medtronic and Norgine. ED: Endoscopic equipment on loan of FujiFilm, and received a research grant from FujiFilm; Honoraria for consultancy from Olympus, Fujifilm, Ambu, InterVenn, Norgine, and Exact Sciences. PM Nykode & Almirall; Speakers' fees from Olympus, GI Supply, Norgine, IPSEN/Mayoly and FujiFilm.

All other authors declare no conflict of interest.

Figures

FIGURE 1
FIGURE 1
Kaplan–Meier curve displaying interval colorectal cancer risk for individuals with and without detectable f‐Hb in their last screening round by time since negative FIT. FIT, fecal immunochemical test; Hb, hemoglobin.

Similar articles

References

    1. Schreuders EH, Ruco A, Rabeneck L, et al. Colorectal cancer screening: a global overview of existing programmes. Gut. 2015;64(10):1637‐1649. - PubMed
    1. Ventura L, Mantellini P, Grazzini G, et al. The impact of immunochemical faecal occult blood testing on colorectal cancer incidence. Dig Liver Dis. 2014;46(1):82‐86. - PubMed
    1. Lauby‐Secretan B, Vilahur N, Bianchini F, Guha N, Straif K. The IARC perspective on colorectal cancer screening. New England Journal of Medicine. 2018;378(18):1734‐1740. - PMC - PubMed
    1. Chiu H‐M, Chen SL‐S, Yen AM‐F, et al. Effectiveness of fecal immunochemical testing in reducing colorectal cancer mortality from the one million Taiwanese screening program. Cancer. 2015;121(18):3221‐3229. - PMC - PubMed
    1. Breekveldt ECH, Lansdorp‐Vogelaar I, Toes‐Zoutendijk E, et al. Colorectal cancer incidence, mortality, tumour characteristics, and treatment before and after introduction of the faecal immunochemical testing‐based screening programme in The Netherlands: a population‐based study. Lancet Gastroenterol Hepatol. 2022;7(1):60‐68. - PubMed